CIK 0001070081 · Large accelerated filer
PTC THERAPEUTICS, INC.
Sign in to watch- Ticker
- PTCT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 043416587
- Phone
- 9082227000
- Business address
- 500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ, 07059
- Former names
- PTC THERAPEUTICS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $7,752,145
- in 10 filings, $7.8M under 10b5-1 plans
Net −$7,752,145. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-24 | Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −401 | 53,599 | ||
| 2026-06-24 | Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −4,922 | 48,677 | ||
| 2026-06-22 | Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER | Option exercise 10b5-1 | +23,749 | $25.69 | $610K | 83,886 |
| 2026-06-22 | Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER | Sale 10b5-1 | −12,130 | $80.61 | $978K | 71,756 |
| 2026-06-22 | Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER | Sale 10b5-1 | −11,619 | $81.21 | $944K | 60,137 |
| 2026-06-22 | Almstead Neil Gregory CHIEF TECHNICAL OPS OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −23,749 | 23,751 | ||
| 2026-06-17 | Utter Christine Marie SVP, CHIEF ACCOUNTING OFFICER | Option exercise 10b5-1 | +19,686 | $25.69 | $506K | 89,885 |
| 2026-06-17 | Utter Christine Marie SVP, CHIEF ACCOUNTING OFFICER | Sale 10b5-1 | −19,686 | $75.56 | $1.5M | 70,199 |
| 2026-06-17 | Utter Christine Marie SVP, CHIEF ACCOUNTING OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −19,686 | 15,314 | ||
| 2026-06-17 | Boulding Mark Elliott EXEC. VP AND CLO | Option exercise 10b5-1 | +8,510 | $46.54 | $396K | 113,722 |
| 2026-06-17 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −6,600 | $78.50 | $518K | 107,122 |
| 2026-06-17 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −1,850 | $79.24 | $147K | 105,272 |
| 2026-06-17 | Boulding Mark Elliott EXEC. VP AND CLO | Option exercise 10b5-1 | +2,012 | $46.54 | $94K | 107,284 |
| 2026-06-17 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −1,703 | $78.50 | $134K | 105,581 |
| 2026-06-17 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −309 | $79.25 | $24K | 105,272 |
| 2026-06-17 | Boulding Mark Elliott EXEC. VP AND CLO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −8,510 | 32,950 | ||
| 2026-06-17 | Boulding Mark Elliott EXEC. VP AND CLO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,012 | 30,938 | ||
| 2026-06-10 | Pauwels Eric CHIEF BUSINESS OFFICER | Sale 10b5-1 | −3,711 | $75.00 | $278K | 73,411 |
| 2026-06-10 | Pauwels Eric CHIEF BUSINESS OFFICER | Option exercise 10b5-1 | +17,566 | $18.01 | $316K | 90,977 |
| 2026-06-10 | Pauwels Eric CHIEF BUSINESS OFFICER | Sale 10b5-1 | −17,566 | $75.00 | $1.3M | 73,411 |
Page 6 of 25 · 493 trades